Pfizer to seek FDA approval for Lyme disease vaccine candidate despite trial miss [CNBC]
Valneva SE - American Depositary Shares (VALN)
Company Research
Source: CNBC
Fhm | Moment | Getty Images Pfizer on Monday said it will seek regulatory approval for a Lyme disease vaccine candidate despite the shot failing a late-stage trial. Pfizer said the vaccine missed the trial's statistical goal because not enough people in the study contracted Lyme disease to be confident in the results. Still, the company said the shot reduced the rate of infection by more than 70% in people who received the vaccine versus placebo, efficacy the company thinks is strong enough to take to regulators. “The efficacy shown in the VALOR study of more than 70% is highly encouraging and creates confidence in the vaccine's potential to protect against this disease that can be debilitating,” Pfizer Chief Vaccines Officer Annaliesa Anderson said in a statement. A vaccine for Lyme disease isn't expected to become a best-seller for Pfizer, with the company's partner Valneva estimating peak annual sales of $1 billion. Pfizer expects overall revenue of around $60 billion this
Show less
Read more
Impact Snapshot
Event Time:
VALN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VALN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VALN alerts
High impacting Valneva SE - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
VALN
News
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Valneva SE – VALNGlobeNewswire
- Pfizer, Valneva to seek approval of Lyme disease vaccine despite mixed study results [Yahoo! Finance]Yahoo! Finance
- Pfizer Lyme Vaccine Data Adds New Angle To Vaccine Portfolio Story [Yahoo! Finance]Yahoo! Finance
- Mixed results for Lyme disease vaccine hit Valneva shares [Yahoo! Finance]Yahoo! Finance
- Valneva Q4 Earnings Call Highlights [Yahoo! Finance]Yahoo! Finance
VALN
Sec Filings
- 3/18/26 - Form 6-K
- 3/17/26 - Form 20-F
- 3/10/26 - Form SCHEDULE
- VALN's page on the SEC website